MB
Pacira Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EXPAREL® (bupivacaine liposome) | Acute Post-Surgical Pain (Pediatric 0 to < 6 years) | Phase 3 |
| PCRX-201 (enekinragene inzadenovec) | Osteoarthritis of the Knee (OAK) | Phase 1 |
| PCRX-2002 | Post-Surgical Pain | Not Specified (Likely Preclinical/Phase 1) |
| ZILRETTA® (triamcinolone acetonide) | Shoulder Osteoarthritis (OA) | Phase 3 |
| iovera® | Spasticity | Phase 2 (or development for new indication) |
Leadership Team at Pacira Biosciences
FD
Frank D. Lee
Chief Executive Officer & Director
BT
Brendan Teehan
Chief Commercial Officer
KW
Kristen Williams, Esq
Chief Administrative Officer & Secretary
JS
Jonathan Slonin, MD
Chief Medical Officer
SC
Shawn Cross
Chief Financial Officer
AM
Anthony Molloy III, Esq.
Chief Legal & Compliance Officer
CY
Christopher Young
Chief Manufacturing Officer
KC
Krys Corbett
Chief Business Officer
LB
Laura Brege
Independent Board Chair
AC
Abraham Ceesay
CEO Rapport Therapeutics